Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

682 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. Horti J, et al. Among authors: figg wd. Oncol Rep. 1998 Jul-Aug;5(4):893-6. doi: 10.3892/or.5.4.893. Oncol Rep. 1998. PMID: 9625840 Clinical Trial.
Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women.
Guetta V, Lush RM, Figg WD, Waclawiw MA, Cannon RO 3rd. Guetta V, et al. Among authors: figg wd. Am J Cardiol. 1995 Nov 15;76(14):1072-3. doi: 10.1016/s0002-9149(99)80302-6. Am J Cardiol. 1995. PMID: 7484866 Clinical Trial.
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. Among authors: figg wd. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.
A preliminary risk-benefit assessment of paclitaxel.
Bitton RJ, Figg WD, Reed E. Bitton RJ, et al. Among authors: figg wd. Drug Saf. 1995 Mar;12(3):196-208. doi: 10.2165/00002018-199512030-00005. Drug Saf. 1995. PMID: 7619331 Review.
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Bitton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR. Bitton RJ, et al. Among authors: figg wd. J Clin Oncol. 1995 Sep;13(9):2223-9. doi: 10.1200/JCO.1995.13.9.2223. J Clin Oncol. 1995. PMID: 7666080 Clinical Trial.
Phase I study of phenylacetate administered twice daily to patients with cancer.
Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Thibault A, et al. Among authors: figg wd. Cancer. 1995 Jun 15;75(12):2932-8. doi: 10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>;2-p. Cancer. 1995. PMID: 7773944 Clinical Trial.
Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D, Figg WD, Herdt J, Kopp WC, Rager H, Steinberg SM, et al. Sausville EA, et al. Among authors: figg wd. Blood. 1995 Jun 15;85(12):3457-65. Blood. 1995. PMID: 7780133 Clinical Trial.
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.
Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. Figg WD, et al. Anticancer Drugs. 1994 Jun;5(3):336-42. doi: 10.1097/00001813-199406000-00012. Anticancer Drugs. 1994. PMID: 7919459
682 results
Jump to page